Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Asymmetric Amination. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN113106078B reveals novel LaLeuDH mutants enabling 1.5M substrate tolerance and coenzyme-free synthesis, offering significant cost reduction in pharmaceutical intermediate manufacturing.
Novel catalytic route for Duvelisib intermediates ensures high purity and scalable production for global pharmaceutical supply chains and cost efficiency.
Patent CN103073456B details a high-purity stereoselective synthesis for rivastigmine intermediates, offering significant cost reduction in API manufacturing and scalable production.
Discover the scalable synthesis of CCR-2 antagonist intermediates via patent CN101160286B. Learn about cost-effective routes and high-purity pharmaceutical manufacturing.
Patent CN114507650A details a high-efficiency biocatalytic route for Clopidogrel intermediates, offering superior stereoselectivity and substrate tolerance for scalable API manufacturing.
Patent CN118324765A reveals a novel Ir-catalyzed route for Duvelisib, offering cost reduction in API manufacturing and enhanced supply chain reliability for global buyers.
Patent CN107540616B details a novel 4-step route to chiral pyrazolamines with 94% ee, offering significant cost reduction and supply chain reliability for agrochemical and pharmaceutical manufacturing.
Patent CN108866021B details a novel transaminase mutant for synthesizing sitagliptin intermediates with >99% ee. Discover cost-effective biocatalytic solutions for API manufacturing.
Patent CN106866574A reveals palladium-catalyzed asymmetric reductive amination for high-purity chiral sulfonamides, offering supply chain reliability and cost efficiency.
Patent CN110668976A reveals a novel Ir-catalyzed asymmetric synthesis for (R)-Rivastigmine intermediates, offering superior yield and purity for reliable pharmaceutical supply chains.
Patent CN109111380B introduces a transition-metal-free method for synthesizing chiral amines via hydrogen borrowing, offering cost reduction in API manufacturing and high stereoselectivity.
Advanced preparation of Maropitant intermediates via transition metal catalysis. High purity, >99% ee, and scalable routes for pharmaceutical manufacturing.
Novel synthetic route for Elacestrant improves yield and purity while reducing hazardous reagent use for reliable supply chain continuity.
Patent CN110862324A discloses a novel iridium-catalyzed asymmetric reductive amination method achieving up to 95% ee for key pharmaceutical intermediates like Cinacalcet.
Patent CN104892443B reveals a high-yield chiral synthesis route for (s)-3-hydroxyadamantane glycine, offering significant cost reduction and supply chain reliability for API manufacturing.
Patent CN112930348A details an enzymatic route for Safraninib, improving yield and reducing waste compared to chiral resolution methods.
Patent CN113292495B details a high-yield synthesis of (S)-amino benazepril intermediate using quinine-derived catalysis, offering significant cost and safety advantages for API manufacturing.
Patent CN103951588A reveals a novel chiral squaramide catalytic route for saxagliptin intermediates, offering significant cost reduction and supply chain reliability for global pharmaceutical manufacturers.
Patent CN110551033B details a novel Ir-catalyzed asymmetric reductive amination method. Achieve high enantioselectivity and cost reduction in chiral amine manufacturing with scalable processes.
Patent CN110551033B details a high-efficiency iridium-catalyzed asymmetric reductive amination method. Achieve superior enantioselectivity and cost reduction in chiral amine manufacturing for pharma and agrochemicals.